Douglas W. Calder

Mr. Calder has served as a director of Zevra Therapeutics since April 2023. Douglas W. Calder, 56, serves as President and a director of Vycellix™, Inc and subsidiaries and affiliates and has served in such roles since 2015. He is also a member of the board of directors for NextGenNK; member of the board of directors of BioFlorida, and a member of the Society for Natural Immunity. Headquartered on the campus of the Moffitt Cancer Center, Tampa, Florida, Vycellix is engineering immune-privileged, cancer-targeting T cells and NK cells without altering the components that control self-recognition and obviating the need for immune-suppressive drugs in the context of allogeneic cell therapies, hence redefining “off-the-shelf” treatment strategies.

Mr. Calder has more than 30 years of life science executive experience, having served in various senior executive roles for Florida-based biotechnology companies and research institutes including Viragen, Accentia Biopharmaceuticals, Biovest International and the Vaccine & Gene Therapy Institute of Florida, as well as having formerly served as a registered financial portfolio manager with a focus on life science equities with the NYSE-member firms, Gruntal & Co. and Dean Witter Reynolds. Mr. Calder received a BA from Florida State University.